BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VOQP) today announced the submission of a 510(k) application to the United States Food and Drug Administration (FDA). The application seeks marketing clearance for Xyfid™ (1% uracil topical), a topical skin preparation intended to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions, by maintaining a moist wound and skin environment. If cleared by the FDA, Xyfid™ will be the company's first commercial product.
